The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Chlorpromazine versus placebo for schizophrenia
Open accessAbstract
BACKGROUND: Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. OBJECTIVES: To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (15 May 2012). We also searched references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and non-affective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care. DATA COLLECTION AND ANALYSIS: We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. We analysed dichotomous data using risk ratio (RR) and estimated the 95% confidence interval (CI) around this. We excluded continuous data if more than 50% of participants were lost to follow-up. Where continuous data were included, we analysed this data using mean difference (MD) with a 95% confidence interval. We used a fixed-effect model. MAIN RESULTS: We inspected over 1100 electronic records. The review currently includes 315 excluded studies and 55 included studies. The quality of the evidence is very low. We found chlorpromazine reduced the number of participants experiencing a relapse compared with placebo during six months to two years follow-up (n = 512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but data were heterogeneous. No difference was found in relapse rates in the short, medium or long term over two years, although data were also heterogeneous. We found chlorpromazine provided a global improvement in a person's symptoms and functioning (n = 1164, 14 RCTs, RR 0.71 CI 0.58 to 0.86). Fewer people allocated to chlorpromazine left trials early ( n = 1831, 27 RCTs, RR 0.64 CI 0.53 to 0.78) compared with placebo. There are many adverse effects. Chlorpromazine is clearly sedating (n = 1627, 23 RCTs, RR 2.79 CI 2.25 to 3.45), it increases a person's chances of experiencing acute movement disorders (n = 942, 5 RCTs, RR 3.47 CI 1.50 to 8.03) and parkinsonism (n = 1468, 15 RCTs, RR 2.11 CI 1.59 to 2.80). Akathisia did not occur more often in the chlorpromazine group than placebo. Chlorpromazine clearly causes a lowering of blood pressure with accompanying dizziness (n = 1488, 18 RCTs, RR 2.38 CI 1.74 to 3.25) and considerable weight gain (n = 165, 5 RCTs, RR 4.92 CI 2.32 to 10.43). AUTHORS' CONCLUSIONS: The results of this review confirm much that clinicians and recipients of care already know but aim to provide quantification to support clinical impression. Chlorpromazine's global position as a 'benchmark' treatment for psychoses is not threatened by the findings of this review. Chlorpromazine, in common use for half a century, is a well-established but imperfect treatment. Judicious use of this best available evidence should lead to improved evidence-based decision making by clinicians, carers and patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
Marshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.249 · Cited by 870
Self-citationThe unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Issues in the meta-analysis of cluster randomized trials
Donner, A., & Klar, N. (2002) · Statistics in Medicine · doi:10.1002/sim.1301 · Cited by 734
Interpreting Results and Drawing Conclusions
Schünemann, H. J., Oxman, A. D., Vist, G. E., Higgins, J. P., Deeks, J. J., Glasziou, P., & Guyatt, G. H. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch12 · Cited by 366
Research works printed but not linked: 481
- Abrams, 1958, Chlorpromazine in the treatment of chronic schizophrenia, Diseases of the Nervous System, 19, 20
- Baker, 1959, A controlled trial of ethylcrotonylurea, British Journal of Psychiatry, 105, 852
- Ban, 1975, Comprehensive clinical studies with thiothixene, Diseases of the Nervous System, 36, 473
- Bishop, 1963, Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients, American Journal of Psychiatry, 120, 180, 10.1176/ajp.120.2.180 · doi:10.1176/ajp.120.2.180
- Borison, 1991, Does sigma receptor antagonism predict clinical antipsychotic efficacy?, Psychopharmacology Bulletin, 27, 103
- Borison, 1990, Sigma receptor antagonism and antipsychotic actions in schizophrenic patients, European Journal of Pharmacology, 183, 23, 10.1016/0014-2999(90)93880-Y · doi:10.1016/0014-2999(90)93880-y
- Chouinard, 1990, A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation, Acta Psychiatria Scandinavica Supplementum, 358, 111, 10.1111/j.1600-0447.1990.tb05301.x · DOI
- Clark, 1961, Chlorpromazine in chronic schizophrenic women. I. Experimental design and effects at maximum point of treatment, Psychopharmacologia, 2, 107, 10.1007/BF00592679 · doi:10.1007/bf00592679
- Clark, 1963, Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects, Psychosomatic Medicine, 25, 212, 10.1097/00006842-196305000-00002 · doi:10.1097/00006842-196305000-00002
- Ray, 1964, Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment, Journal of Nervous and Mental Diseases, 138, 348, 10.1097/00005053-196404000-00005 · doi:10.1097/00005053-196404000-00005
- Clark, 1970, The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients, Clinical Pharmacology and Therapeutics, 11, 883, 10.1002/cpt1970116883 · doi:10.1002/cpt1970116883
- Clark, 1967, Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships, Psychosomatic Medicine, 29, 634, 10.1097/00006842-196711000-00008 · doi:10.1097/00006842-196711000-00008
- Clark, 1968, Evaluation of trifluperidol in chronic schizophrenia, Psychopharmacologia, 12, 193, 10.1007/BF00403773 · doi:10.1007/bf00403773
- Clark, 1968, Evaluation of butaperazine in chronic schizophrenia, Clinical Pharmacology and Therapeutics, 97, 57
- Clark, 1970, The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients, Clinical Pharmacology and Therapeutics, 11, 883, 10.1002/cpt1970116883 · doi:10.1002/cpt1970116883
- Clark, 1970, Molindone in chronic schizophrenia, Clinical Pharmacology and Therapeutics, 11, 680, 10.1002/cpt1970115680 · doi:10.1002/cpt1970115680
- Serafetinides, 1971, The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine, International Pharmacopsychiatry, 6, 77, 10.1159/000468256 · doi:10.1159/000468256
- Clark, 1970, The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients, Clinical Pharmacology and Therapeutics, 11, 883, 10.1002/cpt1970116883 · doi:10.1002/cpt1970116883
- Clark, 1972, Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships, Archives of General Psychiatry, 27, 479, 10.1001/archpsyc.1972.01750280047009 · doi:10.1001/archpsyc.1972.01750280047009
- Clark, 1970, Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships, Psychopharmacologia, 18, 260, 10.1007/BF00412672 · doi:10.1007/bf00412672
- Serafetinides, 1972, EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking, Biological Psychiatry, 4, 251
- Clark, 1969, Phenothiazines in schizophrenics, Psychopharmacology Bulletin, 6, 37
- Clark, 1971, Drug treatment in newly admitted schizophrenic patients, Archives of General Psychiatry, 25, 404, 10.1001/archpsyc.1971.01750170020004 · doi:10.1001/archpsyc.1971.01750170020004
- Clark, 1972, Evaluation of loxapine succinate in chronic schizophrenia, Diseases of the Nervous System, 33, 783
- Serafetinides, 1971, The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects, International Pharmacopsychiatry, 6, 38, 10.1159/000468249 · doi:10.1159/000468249
- Clark, 1977, Evaluation of butaclamol in chronic schizophrenic patients, Journal of Clinical Pharmacology, 17, 529, 10.1002/j.1552-4604.1977.tb05646.x · doi:10.1002/j.1552-4604.1977.tb05646.x
- Cohen, 1968, Family interaction patterns, drug treatment, and change in social aggression, Archives of General Psychiatry, 19, 50, 10.1001/archpsyc.1968.01740070052008 · doi:10.1001/archpsyc.1968.01740070052008
- Graupner, 1972, Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments, Psychopharmacologia, 27, 343, 10.1007/BF00429387 · doi:10.1007/bf00429387
- Cole, 1964, Phenothiazine treatment in acute schizophrenia, Archives of General Psychiatry, 10, 246, 10.1001/archpsyc.1964.01720210028005 · DOI · Paper page
- Goldberg, 1965, Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment, British Journal of Psychiatry, 111, 120, 10.1192/bjp.111.471.120 · DOI
- Goldberg, 1968, Schizophrenic subtypes defined by response to drugs and placebo, Diseases of the Nervous System, 29, 153
- Cooper SJ Raniwalla J Welch C Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia Melbourne, Australia 1996 · doi:10.1016/0924-977x(96)87990-9
- Cooper, 2000, A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia, Acta Psychiatrica Scandinavica, 101, 218, 10.1034/j.1600-0447.2000.101003218.x · DOI
- Dean, 1958, Schizophrenia treated with and without chlorpromazine, Rocky Mountain Medical Journal, 55, 47
- Engelhardt, 1964, Phenothiazines in prevention of psychiatric hospitalization, Archives of General Psychiatry, 11, 162, 10.1001/archpsyc.1964.01720260056007 · doi:10.1001/archpsyc.1964.01720260056007
- Engelhardt, 1960, Prevention of psychiatric hospitalization with use of psychopharmacological agents, JAMA, 173, 147, 10.1001/jama.1960.03020200019005 · doi:10.1001/jama.1960.03020200019005
- Engelhardt, 1969, Physician bias and the double-blind, Archives of General Psychiatry, 20, 315, 10.1001/archpsyc.1969.01740150059009 · DOI
- Engelhardt, 1963, Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure, JAMA, 186, 981, 10.1001/jama.1963.03710110033006 · doi:10.1001/jama.1963.03710110033006
- Engelhardt, 1967, Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation, Archives of General Psychiatry, 16, 98, 10.1001/archpsyc.1967.01730190100013 · DOI
- Freedman, 1967, On the modification of paranoid symptomatology, Journal of Nervous and Mental Disease, 144, 29, 10.1097/00005053-196701000-00006 · doi:10.1097/00005053-196701000-00006
- Freedman, 1970, On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines, Journal of Nervous and Mental Disease, 150, 68, 10.1097/00005053-197001000-00008 · doi:10.1097/00005053-197001000-00008
- Rosen, 1968, The hospitalization proneness scale as a predictor of response to phenothiazine treatment, Journal of Nervous and Mental Disease, 6, 476, 10.1097/00005053-196806000-00007 · doi:10.1097/00005053-196806000-00007
- Belmont, 1963, The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual analytic responsivity and memory as revealed in rorschach responses, Journal of Nervous and Mental Disease, 137, 42, 10.1097/00005053-196307000-00004 · doi:10.1097/00005053-196307000-00004
- Fink, 1963, Comparative studies of chlorpromazine and imipramine. I. Drug discriminating patterns, Neuropsychopharmacology, 3, 370
- Klein, 1967, Importance of psychiatric diagnosis in prediction of clinical drug effects, Archives of General Psychiatry, 16, 118, 10.1001/archpsyc.1967.01730190120016 · DOI · Paper page
- Klein, 1968, Psychiatric diagnosis and a typology of clinical drug effects, Psychopharmacologia, 13, 359, 10.1007/BF00404952 · DOI
- Klein, 1968, Prediction of drug effect by diagnostic decision tree, Diseases of the Nervous System, 29, 159
- Levenstein, 1966, Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years, American Journal of Psychiatry, 122, 1102, 10.1176/ajp.122.10.1102 · DOI
- Fleming, 1959, A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis, British Journal of Psychiatry, 105, 349
- Grygier, 1958, Chlorpromazine used with an intensive occupational therapy program. A.M.A, Archives of Neurology and Psychiatry, 79, 697, 10.1001/archneurpsyc.1958.02340060095013 · doi:10.1001/archneurpsyc.1958.02340060095013
- Gwynne, 1962, Efficacy of trifluoperazine on withdrawal in chronic schizophrenia, Journal of Nervous and Mental Disease, 134, 451, 10.1097/00005053-196205000-00008 · doi:10.1097/00005053-196205000-00008
- Hall, 1955, A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics, Journal of Nervous and Mental Disease, 122, 301, 10.1097/00005053-195510000-00001 · doi:10.1097/00005053-195510000-00001
- Hollister, 1966, Phenothiazine derivatives and morphologic changes in the liver, American Journal of Psychiatry, 123, 211, 10.1176/ajp.123.2.211 · doi:10.1176/ajp.123.2.211
- Hamill, 1975, The immediate effects of chlorpromazine in newly admitted schizophrenic patients, American Journal of Psychiatry, 132, 1023, 10.1176/ajp.132.10.1023 · doi:10.1176/ajp.132.10.1023
- Hamilton, 1960, A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics, British Journal of Psychiatry, 106, 40
- Hankoff, 1962, A reference study of ataraxics. A two-week double blind outpatient evaluation, Journal of New Drugs, 2, 173, 10.1177/009127006200200305 · doi:10.1177/009127006200200305
- Hine, 1958, Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic, Journal of Nervous and Mental Diseases, 127, 220, 10.1097/00005053-195809000-00002 · doi:10.1097/00005053-195809000-00002
- Goldberg, 1977, Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy, Archives of General Psychiatry, 34, 171, 10.1001/archpsyc.1977.01770140061008 · DOI · Paper page
- Hogarty, 1973, Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates, Archives of General Psychiatry, 28, 54, 10.1001/archpsyc.1973.01750310038007 · DOI · Paper page
- Hogarty, 1974, Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients, Archives of General Psychiatry, 31, 609, 10.1001/archpsyc.1974.01760170011002 · DOI · Paper page
- Hogarty, 1974, Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates, Archives of General Psychiatry, 31, 603, 10.1001/archpsyc.1974.01760170005001 · DOI · Paper page
- Hogarty, 1977, Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients, Archives of General Psychiatry, 34, 297, 10.1001/archpsyc.1977.01770150055005 · DOI · Paper page
- Hogarty, 1984, Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate, Journal of Clinical Psychopharmacology, 4, 17, 10.1097/00004714-198402000-00003 · doi:10.1097/00004714-198402000-00003
- Klein, 1973, Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients, Archives of General Psychiatry, 29, 480, 10.1001/archpsyc.1973.04200040034006 · doi:10.1001/archpsyc.1973.04200040034006
- Kurland, 1961, The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness, Journal of Nervous and Mental Disease, 133, 1, 10.1097/00005053-196107000-00001 · doi:10.1097/00005053-196107000-00001
- Kurland, 1961, Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations, Journal of Nervous and Mental Disease, 132, 61, 10.1097/00005053-196101000-00010 · doi:10.1097/00005053-196101000-00010
- Kurland, 1959, Pre-admission drug treatment of state psychiatric hospital patients, American Journal of Psychiatry, 115, 1028, 10.1176/ajp.115.11.1028 · doi:10.1176/ajp.115.11.1028
- Kurland, 1960, The phenothiazine tranquilizers - their neurological complications and significance, Psychosomatics, 1, 192, 10.1016/S0033-3182(60)72984-0 · doi:10.1016/s0033-3182(60)72984-0
- Letemendia, 1967, Chlorpromazine and the untreated chronic schizophrenic: a long-term trial, British Journal of Psychiatry, 113, 950, 10.1192/bjp.113.502.950 · doi:10.1192/bjp.113.502.950
- Nishikawa, 1982, Prophylactic effect of neuroleptics in symptom-free schizophrenics, Psychopharmacology, 77, 301, 10.1007/BF00432759 · DOI
- Payne, 1960, A comparison of trifluopromazine, chlorpromazine and a placebo in twenty-one chronic schizophrenic patients, Manitoba Medical Review, 196
- Peet, 1981, Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo, British Journal of Psychiatry, 139, 105, 10.1192/bjp.139.2.105 · DOI
- Crane, 1968, Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs, Agressologie, 2, 209
- Long, 1968, Incidence and significance of chlorpromazine-induced eye changes, Diseases of the Nervous System, 29, 19
- Gardos, 1982, A 12-year follow-up study of chronic schizophrenics, Hospital and Community Psychiatry, 33, 983
- Mandel, 1968, Agranulocyctosis and phenothiazines, Diseases of the Nervous System, 29, 32
- Prien, 1968, High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group, Archives of General Psychiatry, 18, 482, 10.1001/archpsyc.1968.01740040098013 · doi:10.1001/archpsyc.1968.01740040098013
- Prien, 1970, Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study, Archives of General Psychiatry, 23, 464, 10.1001/archpsyc.1970.01750050080011 · doi:10.1001/archpsyc.1970.01750050080011
- Prien, 1968, Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication, British Journal of Psychiatry, 115, 679, 10.1192/bjp.115.523.679 · DOI
- Prien, 1970, Indications for high dose chlorpromazine therapy in chronic schizophrenia, Diseases of the Nervous System, 31, 739
- Ramu, 1999, A double blind controlled study on the role of brahmyadiyoga and tagara in navonmada (acute schizophrenia), 59
- Ramu, 1999, A DOUBLE BLIND controlled study on the role of brahmyadiyoga and tagara in jirnomada (chronic schizophrenia), 77
- Rappaport, 1978, Are there schizophrenics for whom drugs may be unnecessary or contraindicated?, International Pharmacopsychiatry, 13, 100, 10.1159/000468327 · DOI
- Reardon, 1966, Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo), Diseases of the Nervous System, 27, 265
- Reschke, 1974, Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia, Diseases of the Nervous System, 35, 112
- Saretsky, 1966, Effects of chlorpromazine on primary-process thought manifestations, Journal of Abnormal Psychology, 71, 247, 10.1037/h0023595 · doi:10.1037/h0023595
- Schiele, 1961, A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients, Journal of Clinical and Experiemental Psychopathology, 22, 151
- Serafetinides, 1973, Psychological effects of single dose antipsychotic medication, Biological Psychiatry, 7, 263
- Serafetinides, 1972, Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives, Journal of Nervous and Mental Diseases, 154, 31, 10.1097/00005053-197201000-00005 · DOI
- Serafetinides, 1973, A method of quantifying EEG for psychopharmacological research, International Pharmacopsychiatry, 8, 245, 10.1159/000468000 · doi:10.1159/000468000
- Serafetinides, 1972, Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics, Journal of Nervous and Mental Diseases, 155, 366, 10.1097/00005053-197211000-00010 · DOI
- Shepherd, 1956, A controlled clinical study of chlorpromazine and reserpine, Journal of Neurology, Neurosurgery and Psychiatry, 19, 232, 10.1136/jnnp.19.3.232 · DOI
- Simon, 1965, Long-term follow-up study of schizophrenic patients, Archives of General Psychiatry, 12, 510, 10.1001/archpsyc.1965.01720350078010 · DOI
- Simon, 1958, A controlled study of the short-term differential treatment of schizophrenia, American Journal of Psychiatry, 114, 1077, 10.1176/ajp.114.12.1077 · doi:10.1176/ajp.114.12.1077
- Smith, 1961, A clinical study of chlorpromazine and chlordiazepoxide, Connecticut State Medical Journal, 25, 153
- Somerville, 1960, Phenothiazine side-effects. Comparison of two major tranquillizers, British Journal of Psychiatry, 106, 1417
- Spohn, 1977, Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics, Archives of General Psychiatry, 34, 633, 10.1001/archpsyc.1977.01770180019001 · DOI · Paper page
- Tetreault, 1969, Comparative study of two drugs and a placebo in chronic schizophrenia, Actualites Pharmacologiques, 22, 221
- Tetreault, 1969, Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients, Diseases of the Nervous System, 30, 74
- Vaughan, 1955, Chlorpromazine in psychiatry, Lancet, 1, 1083, 10.1016/S0140-6736(55)90587-0 · doi:10.1016/s0140-6736(55)90587-0
- Walsh, 1959, The relative efficacy of "Vespral" and chlorpromazine in the treatment of a group of chronic schizophrenic patients, British Journal of Psychiatry, 105, 199
- Weckowicz, 1960, Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients, Diseases of the Nervous System, 21, 527
- Xiong, 1994, A double-blind comparative study of pheytoin and chlorpromazine in chronic schizophrenics, Medical Journal of Chinese Civil Administration, 6, 160
- Abse, 1960, Evaluation of tranquilizing drugs in the management of acute mental disturbance, American Journal of Psychiatry, 117, 973, 10.1176/ajp.116.11.973 · doi:10.1176/ajp.116.11.973
- Acker, 1965, An exploration of the autonomic effects of phenothiazines, Psychopharmacologia, 7, 150, 10.1007/BF00403638 · doi:10.1007/bf00403638
- Affleck, 1966, The action of a medication and the physician's expectations, Nebraska State Medical Journal, 51, 331
- Agarwal, 1985, Role of ECT phenothiazine combination in schizophrenia, Indian Journal of Psychiatry, 27, 233
- Akimoto, 1966, Current status of pharmacotherapy in schizophrenia, Folia Psychiatrica et Neurologica Japonica, 20, 1
- Alpert, 1966, Evaluation of treatment with recorded interviews, American Journal of Psychiatry, 122, 1258, 10.1176/ajp.122.11.1258 · doi:10.1176/ajp.122.11.1258
- Alpert, 1978, Paradoxical reaction to L-dopa in schizophrenic patients, American Journal of Psychiatry, 135, 1329, 10.1176/ajp.135.11.1329 · doi:10.1176/ajp.135.11.1329
- Alson, 1964, The use of adjective check lists with psychotic patients: the problem of pseudo-responses, Journal of Clinical Psychology, 20, 462, 10.1002/1097-4679(196410)20:4<462::AID-JCLP2270200415>3.0.CO;2-V · doi:10.1002/1097-4679(196410)20:4<462::aid-jclp2270200415>3.0.co;2-v
- Aman, 1985, Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment, Journal of Mental Deficiency Research, 29, 187
- Amin, 1977, A standard-controlled clinical study with benzquinamide in the treatment of chronic schizophrenic patients, Psychopharmacology Bulletin, 13, 20
- Ananth, 1972, Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo-controlled study, Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie, 5, 406
- Andrews, 1976, A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients, British Journal of Psychiatry, 128, 451, 10.1192/bjp.128.5.451 · DOI
- Ashcroft, 1961, A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia, Journal of Mental Science (British Journal of Psychiatry from 1963), 107, 287
- Ayers, 1984, Subjective response to antipsychotic drugs: failure to replicate predictions of outcome, Journal of Clinical Psychopharmacology, 4, 89, 10.1097/00004714-198404020-00005 · doi:10.1097/00004714-198404020-00005
- Azima, 1954, Effects of Largactil in mental syndomes, Canadian Medical Association Journal, 71, 116
- Bagadia, 1981, Evaluation of cognitive effects of ECT: preliminary observations, Indian Journal of Psychiatry, 23, 324
- Ban, 1977, Negative findings with megavitamins in schizophrenic patients - preliminary report, Communications in Psychopharmacology, 1, 119
- Hoffer, 1975, Megavitamin treatment of schizophrenia, Canadian Psychiatric Association Journal, 20, 492, 10.1177/070674377502000621 · doi:10.1177/070674377502000621
- Beech, 1990, The effect of a small dose of chlorpromazine on a measure of 'cognitive inhibition', Personality and Individual Differences, 11, 1141, 10.1016/0191-8869(90)90026-N · DOI
- Benaim, 1960, The effect of chlorpromazine on the incidence of epileptic phenomena during insulin coma therapy: A statistical investigation, Journal of Mental Science, 106, 317, 10.1192/bjp.106.442.317 · doi:10.1192/bjp.106.442.317
- Bennett, 1956, Clinical investigation of chlorpromazine and reserpine in private psychiatric practice, American Journal of Psychiatry, 112, 782, 10.1176/ajp.112.10.782 · doi:10.1176/ajp.112.10.782
- Blumberg, 1964, Effects of chlorpromazine and imipramine on systolic blood pressure in psychiatric patients: Relationships to age, diagnosis and initial blood pressure, Journal of Psychiatric Research, 2, 51, 10.1016/0022-3956(64)90029-9 · doi:10.1016/0022-3956(64)90029-9
- Blumberg, 1969, Chlorpromazine-procyclidine and imipramine: effects on thyroid function in psychiatric patients, Clinical Pharmacology and Therapeutics, 10, 350, 10.1002/cpt1969103350 · DOI
- Boullin, 1975, Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine, British Journal of Clinical Pharmacology, 2, 29, 10.1111/j.1365-2125.1975.tb00468.x · DOI
- Bowes, 1956, The ataractic drugs: the present position of chlorpromazine, frenquel, pacatal, and reserpine in the psychiatric hospital, American Journal of Psychiatry, 113, 530, 10.1176/ajp.113.6.530 · doi:10.1176/ajp.113.6.530
- Bressler, 1971, A comparison between chlorpromazine and thiothixene in a Veterans Administration Hospital population, Psychosomatics, 12, 275, 10.1016/S0033-3182(71)71519-9 · doi:10.1016/s0033-3182(71)71519-9
- Brizer, 1985, Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia, American Journal of Psychiatry, 142, 1106, 10.1176/ajp.142.9.1106 · doi:10.1176/ajp.142.9.1106
- Burnett, 1975, The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial, Diseases of the Nervous System, 36, 625
- Cabrera Gomez, 1994, Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon, Biotherapy, 7, 27, 10.1007/BF01878151 · doi:10.1007/bf01878151
- Caffey, 1963, Phenothiazine excretion in chronic schizophrenics, American Journal of Psychiatry, 120, 578, 10.1176/ajp.120.6.578 · doi:10.1176/ajp.120.6.578
- Caffey, 1964, Discontinuation or reduction of chemotherapy in chronic schizophrenics, Journal of Chronic Diseases, 17, 347, 10.1016/0021-9681(64)90075-X · DOI
- Caffey, 1975, Practical considerations on treatment with antipsychotic preparations, Zhurnal Nevropatologii i Psikhiatrii, 75, 1399
- Campbell, 1972, Acute responses of schizophrenic children to a sedative and a 'stimulating' neuroleptic: a pharmacologic yardstick, Current Therapeutic Research, 14, 759
- Campbell, 1970, Thiothixene in young disturbed children. A pilot study, Archives of General Psychiatry, 23, 70, 10.1001/archpsyc.1970.01750010072013 · DOI
- Cardone, 1969, Chlorpromazine and body image. Effects on chronic schizophrenics, Archives of General Psychiatry, 20, 576, 10.1001/archpsyc.1969.01740170080012 · doi:10.1001/archpsyc.1969.01740170080012
- Casey, 1960, Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo, Archives of General Psychiatry, 2, 210, 10.1001/archpsyc.1960.03590080086012 · DOI
- Casey, 1961, Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine, American Journal of Psychiatry, 117, 997, 10.1176/ajp.117.11.997 · doi:10.1176/ajp.117.11.997
- Chacon, 1973, Clinical and work performance variables in phenothiazine therapy of schizophrenia, Acta Psychiatrica Scandinavica, 49, 65, 10.1111/j.1600-0447.1973.tb04399.x · doi:10.1111/j.1600-0447.1973.tb04399.x
- Chacon, 1972, Work study in the assessment of the effects of phenothiazines in schizophrenia, Comprehensive Psychiatry, 13, 549, 10.1016/0010-440X(72)90055-7 · doi:10.1016/0010-440x(72)90055-7
- Childers, 1961, A comparison of the effectiveness of triluoperazine and chlorpromazine in schizophrenia, American Journal of Psychiatry, 118, 552, 10.1176/ajp.118.6.552 · doi:10.1176/ajp.118.6.552
- Chouinard, 1977, Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit, Journal of Clinical Pharmacology, 17, 162, 10.1002/j.1552-4604.1977.tb04602.x · doi:10.1002/j.1552-4604.1977.tb04602.x
- Chouinard-G, 1983, Fluspirilene in the treatment of newly admitted schizophrenic patients, Psychopharmacology Bulletin., 19, 136
- Claghorn, 1983, The current status of clozapine, Psychopharmacology Bulletin, 19, 138
- Clark, 1970, Ocular pigment deposits: drug-induced false-positives, JAMA, 214, 2339, 10.1001/jama.1970.03180130071025 · doi:10.1001/jama.1970.03180130071025
- Clark, 1970, The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients, Clinical Pharmacology and Therapeutics, 11, 883, 10.1002/cpt1970116883 · doi:10.1002/cpt1970116883
- Clark, 1976, A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients, 191
- Clark, 1975, A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients, Psychopharmacology Bulletin, 11, 28
- Clark, 1978, Chlorpromazine kinetics and clinical response, Psychopharmacology Bulletin, 14, 43
- Cobb, 1956, Changes in the electroencephalogram, the electrodermogram, and the electromyogram provoked by chlorpromazine in man, Abstracts of World Medicine, 20, 177
- Cole, 1967, Differences in clinical effects of three phenothiazines in "acute" schizophrenia, Diseases of the Nervous System, 28, 369
- Coons, 1962, Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients, Canadian Psychiatric Association Journal, 7, 159, 10.1177/070674376200700403 · doi:10.1177/070674376200700403
- Cowden, 1956, Chlorpromazine: alone and as an adjunct to group psychotherapy in the treatment of psychiatric patients, American Journal of Psychiatry, 4, 898, 10.1176/ajp.112.11.898 · DOI
- Crane, 1970, High doses of trifluperazine and tardive dyskinesia, Archives of Neurology, 22, 176, 10.1001/archneur.1970.00480200082009 · doi:10.1001/archneur.1970.00480200082009
- Crane, 1971, Persistence of neurological symptoms due to neuroleptic drugs, American Journal of Psychiatry, 127, 1407, 10.1176/ajp.127.10.1407 · doi:10.1176/ajp.127.10.1407
- Crow, 1986, The Northwick Park study of first episodes of schizophrenia. II. A randomised controlled trial of prophylactic neuroleptic treatment, British Journal of Psychiatry, 148, 120, 10.1192/bjp.148.2.120 · DOI · Paper page
- Johnstone, 1986, The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission, British Journal of Psychiatry, 148, 115, 10.1192/bjp.148.2.115 · DOI · Paper page
- MacMillan, 1986, The Northwick Park study of first episodes of schizophrenia. III. Short-term outcome in trial entrants and trial eligible patients, British Journal of Psychiatry, 148, 128, 10.1192/bjp.148.2.128 · DOI
- Curry, 1972, Double-blind trial of fluphenazine decanoate, Lancet, 2, 543, 10.1016/S0140-6736(72)91943-5 · doi:10.1016/s0140-6736(72)91943-5
- Cutler, 1957, Effects of "tranquilizers" upon pathological activity in psychotic patients: II. Reserpine, Archives of Neurology and Psychiatry, 78, 61, 10.1001/archneurpsyc.1957.02330370075012 · doi:10.1001/archneurpsyc.1957.02330370075012
- Dally, 1966, Treatment and outcome of anorexia nervosa, British Medical Journal, 2, 793, 10.1136/bmj.2.5517.793 · DOI
- Danion, 1992, Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers, Psychopharmacology, 108, 345, 10.1007/BF02245122 · DOI
- Daston, 1958, Stylus maze performance of chronic schizophrenics taking chlorpromazine, Journal of Consulting Psychology, 22, 384, 10.1037/h0041643 · doi:10.1037/h0041643
- Daston, 1959, Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics, Journal of Clinical Psychology, 15, 106, 10.1002/1097-4679(195901)15:1<106::AID-JCLP2270150128>3.0.CO;2-E · doi:10.1002/1097-4679(195901)15:1<106::aid-jclp2270150128>3.0.co;2-e
- Davies, 1973, The use of chlorpromazine in schizophrenia, Nursing Times, 69, 1694
- Dean, 1967, Mefenamic acid and chlorpromazine in porphyria variegata, South African Medical Journal, 41, 925
- Denber, 1955, Studies on Mescaline. VI. Therapeutic Aspects of the Mescaline-Chlorpromazine Combination, Journal of Nervous and Mental Diseases, 122, 463, 10.1097/00005053-195511000-00008 · doi:10.1097/00005053-195511000-00008
- Denber, 1956, Chlorpromazine in the treatment of mental illness. III. The problem of depression, American Journal of Psychiatry, 112, 1021, 10.1176/ajp.112.12.1021 · doi:10.1176/ajp.112.12.1021
- Denber, 1957, Chlorpromazine-diethazine in the treatment of depression, Diseases of the Nervous System, 18, 76
- Boer, 2000, Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia, Human Psychopharmacology, 15, 179, 10.1002/(SICI)1099-1077(200004)15:3<179::AID-HUP156>3.0.CO;2-N · DOI
- Desager, 1988, Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic, Psychopharmacology Berlin, 96, 63, 10.1007/BF02431534 · DOI
- Douglas, 1969, A comparison of mesoridazine and chlorpromazine in chronic psychiatric patients, Journal of Clinical Pharmacology and The Journal of New Drugs, 9, 176
- Downing, 1963, Effect of phenothiazines on the thinking of acute schizophrenics, Perceptual and Motor Skills, 17, 511, 10.2466/pms.1963.17.2.511 · DOI
- Dube, 1981, Efficacy of lithium in schizophrenia, Indian Journal of Psychiatry, 23, 193
- Eitan, 1992, Effects of antipsychotic drugs on memory functions of schizophrenic patients, Acta Psychiatrica Scandinavica, 85, 74, 10.1111/j.1600-0447.1992.tb01446.x · DOI · Paper page
- Ekdawi, 1966, A controlled trial of anti-parkinson drugs in drug-induced parkinsonism, British Journal of Psychiatry, 112, 633, 10.1192/bjp.112.487.633 · doi:10.1192/bjp.112.487.633
- Elkes, 1954, Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients, British Medical Journal, 2, 560, 10.1136/bmj.2.4887.560 · DOI
- Feldman, 1956, A controlled, blind study of effects of thorazine on psychotic behavior, Bulletin of the Menninger Clinic, 20, 25
- Fink, 1958, Comparative study of chlorpromazine and insulin coma in therapy of psychosis, Journal of the American Medical Association, 166, 1846, 10.1001/jama.1958.02990150042009 · doi:10.1001/jama.1958.02990150042009
- Fink, 1965, Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders, Psychopharmacologia, 7, 27, 10.1007/BF00404162 · DOI
- Fleming, 1958, Investigation of a new compound, B.W.203, and of Chlorpromazine in the treatment of psychosis, British Journal of Psychiatry, 104, 749
- Foote, 1958, Combined Chlorpromazine and Reserpine in the treatment of chronic psychotics, British Journal of Psychiatry, 104, 201
- Forrest, 1967, The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo, Journal of Psychiatric Research, 5, 281, 10.1016/0022-3956(67)90016-7 · DOI
- Freed, 1956, Treatment of hyperkinetic emotionally disturbed children with prolonged administration of chlorpromazine, American Journal of Psychiatry, 113, 22, 10.1176/ajp.113.1.22 · doi:10.1176/ajp.113.1.22
- Freedman, 1965, Communication of body complaints and paranoid symptom change under conditions of phenothiazine treatment, Journal of Personality and Social Psychology, 1, 310, 10.1037/h0021923 · doi:10.1037/h0021923
- Freeman, 1956, Effects of chlorpromazine and reserpine in chronic schizophrenic patients, Diseases of the Nervous System, 17, 213
- Freeman, 1956, Effects of chlorpromazine on chronic lobotomized schizophrenic patients. A.M.A, Archives of Neurology and Psychiatry, 76, 500, 10.1001/archneurpsyc.1956.02330290044005 · doi:10.1001/archneurpsyc.1956.02330290044005
- Freeman, 1973, A double blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics, Diseases of the Nervous System, 34, 289
- Friedhoff, 1960, The effect of chlorpromazine on the variability of motor task performance in schizophrenics, Journal of Nervous and Mental Disease, 131, 110, 10.1097/00005053-196008000-00003 · doi:10.1097/00005053-196008000-00003
- Fromm, 1956, Controlled study on the value of chlorpromazine in allaying anxiety, Diseases of the Nervous System, 17, 16
- Gaitz, 1955, Evaluation of Chlorpromazine in Comparison with other Methods of treatments of hospitalized psychiatric patients, using the lorr multidimensional scale for rating psychiatric patients, Psychiatric Research Reports, 1, 1984
- Galbrecht, 1968, Predicting response to phenothiazines: the right drug for the right patient, Journal of Nervous and Mental Disease, 147, 173, 10.1097/00005053-196808000-00009 · doi:10.1097/00005053-196808000-00009
- Galdi, 1988, Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics, Canadian Journal of Psychiatry, 33, 816, 10.1177/070674378803300906 · doi:10.1177/070674378803300906
- Gallant, 1963, The relationship between serotonin antagonism and tranquilizing activity, American Journal of Psychiatry, 119, 882, 10.1176/ajp.119.9.882 · doi:10.1176/ajp.119.9.882
- Gallant, 1967, BL-KR140: a controlled evaluation in chronic schizophrenic patients previously stabilized on chlorpromazine, Current Therapeutic Research, 9, 447
- Gardner, 1955, Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia, Psychiatric Research Reports, 1, 77
- Gardos, 1968, Trifluoperazine and chlorpromazine in combination and individually, Current Therapeutic Research Clinical and Experimental, 10, 609
- Gardos, 1976, Maintenance antipsychotic therapy: is the cure worse than the disease?, American Journal of Psychiatry, 133, 32, 10.1176/ajp.133.1.32 · DOI · Paper page
200 of 481 shown
Cited by
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Treatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., De Silva, M., Hosman, C., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61240-9 · Cited by 930
National Service Framework for Mental Health
Thornicroft, G. (2000) · Psychiatric Bulletin · doi:10.1192/pb.24.6.203 · Cited by 640
Metadata
- Authors
- Adams, C. E., Awad, G. A., Rathbone, J., Thornley, B., & Soares-Weiser, K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-01-06
- Volume
- 2015
- Issue
- 11
- Pages
- CD000284-CD000284
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1910485579
- Cited by
- 171
- References
- 11
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chlorpromazine versus placebo for schizophrenia. https://app.cochat.ai/papers/10.1002/14651858.cd000284.pub3
- The paper
- Adams, C. E., Awad, G. A., Rathbone, J., Thornley, B., & Soares-Weiser, K. (2014). Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd000284.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.